Benjamin T. Dake, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 18,969 shares at $21.62 ($412K) on 2023-05-08, disclosed to the SEC on 2023-05-09.
Scheduled sale ($412k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.62 | 8,685 | $188K | 45.6% |
| 2 | $21.62 | 8,685 | $188K | 45.6% |
| 3 | $22.74 | 1,599 | $36K | 8.8% |
| Total | $21.71 avg | 18,969 | $412K | 100% |
| Filing → |
| AVTE | SELL | 2024-03-28 | $619K | — | Filing → |
| AVTE | SELL | 2024-03-27 | $192K | — | Filing → |
| AVTE | SELL | 2024-03-20 | $1.8M | — | Filing → |